Announcements Trials
Browse Landscape

Phase

Phase 2 39Phase 1 15Phase 3 13Phase 1/2 6Phase 4 4Phase NA 1Phase EARLY_PHASE1 1Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 20Gynecologic 17Gastrointestinal 17Thoracic 11Genitourinary 5CNS 5Sarcoma 4Other solid neoplasm 2Breast 2Tumor-Agnostic 1Plasma cell 1Lymphoid 1

Conditions

Lymphoma, T-Cell 1Immunoblastic Lymphadenopathy 1

Interventions

Cyclophosphamide 47Rituximab 34Exercise 25fludarabine phosphate 24Methotrexate 24Blood Specimen Collection 23Vincristine 21Cytarabine 21Radiotherapy 20Filgrastim 19Peripheral Blood Stem Cell Transplantation 18Whole-Body Irradiation 17Prednisone 16Melphalan 16Etoposide 16Cyclosporine 16Methods 15Dexamethasone 15Busulfan 15Antilymphocyte Serum 15fludarabine 14Doxorubicin 14Educational Status 13Mycophenolic Acid 12Magnetic Resonance Spectroscopy 11Early Intervention, Educational 11Therapeutics 10Surveys and Questionnaires 9Standard of Care 9Prednisolone 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Cisplatin × Lymphoid × Clear all
NCT05821192 2023-04-20

Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

The First Hospital of Jilin University

Phase NA Unknown
34 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡